Drug intelligence / Profile preview

MER769

Development stage: Preclinical
Lead developer: Merida Biosciences
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

MER769 is a therapeutic monoclonal antibody developed by Merida Biosciences for the treatment of various IgE-mediated allergic diseases, including food allergy, severe asthma, atopic dermatitis, and urticaria. The antibody is designed to neutralize and eliminate circulating Immunoglobulin E (IgE) antibodies, thereby preventing the activation of mast cells and basophils that drive the allergic inflammatory response. As of 2024, MER769 is in the IND-enabling phase of development.

Other names: MER769MER-769MER 769

Targets

FCGR2B (Fc gamma receptor IIB)IgE (Immunoglobulin E)

Beyond the preview

Go deeper on MER769.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MER769.

Explore the full profile